BioMerieux Offer For Organon Teknika Would Create $1 Bil. Diagnostics Unit
This article was originally published in The Gray Sheet
Executive Summary
BioMerieux-Pierre Fabre's Feb. 15 offer to buy Organon Teknika's diagnostic business would increase the French company's worldwide diagnostic revenues almost 44% to roughly $0.9 bil. annually.
You may also be interested in...
New bioMérieux Assay Detects Broadest Range Of HIV-1 Load Levels
A "real-time" version of bioMérieux' NucliSens nucleic acid diagnostic system, the NucliSens EasyQ,will be available in the U.S. by the end of 2002, pending FDA approval of a PMA supplement, according to bioMérieux
New bioMérieux Assay Detects Broadest Range Of HIV-1 Load Levels
A "real-time" version of bioMérieux' NucliSens nucleic acid diagnostic system, the NucliSens EasyQ,will be available in the U.S. by the end of 2002, pending FDA approval of a PMA supplement, according to bioMérieux
Akzo Nobel
Dutch conglomerate completes divestiture of the in vitro diagnostics business of its Organon Teknika unit to bioMerieux for about $260 mil. Initially proposed in February, the move will expand bioMerieux' diagnostics revenues to about $1 bil. and allow Organon to focus on its core pharmaceuticals business (1"The Gray Sheet" Feb. 19, 2001, p. 14)